ADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering
This year at the American Diabetes Association (ADA) Scientific Sessions, new Phase III data were presented evaluating the safety and …
Post
-
-
ADA26: Early data for teplizumab demonstrates promise for slowing T1D progression
During the 2026 American Diabetes Association (ECO) Scientific Sessions in New Orleans, a real-world cohort of type 1 diabetic (T1D) …
-
Study explores gaps in Europe’s steatotic liver disease response plans
The growing prevalence of metabolic dysfunction-associated steatotic liver disease and non-alcoholic steatotic hepatitis (MASLD/NASH) poses a growing public health risk, …
-
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials
Gilead Sciences and MSD’s human immunodeficiency virus (HIV) once weekly tablet combination has met primary endpoints in two Phase III …
-
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA
AstraZeneca has unveiled data from two Phase IIb trials of its in-licensed oral glucagon-like peptide-1 receptor agonist (GLP-1RA), touting a …
-
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA
AstraZeneca has unveiled data from two Phase IIb trials of its in-licensed oral glucagon-like peptide-1 receptor agonist (GLP-1RA), touting a …
-
Alkeus doses first patient in Phase III NORTHSTAR trial
Alkeus Pharmaceuticals has dosed the first patient in its pivotal global Phase III NORTHSTAR study, investigating oral gildeuretinol (ALK-001) for …
-
Coya Therapeutics begins extension phase of ALSTARS trial for COYA 302
Coya Therapeutics has initiated the blinded extension phase of the ALSTARS trial, evaluating the safety and efficacy of COYA 302 …
-
ADA26: Kidney disease analysis given spotlight
At this year’s American Diabetes Association (ADA) congress, while obesity and diabetes treatments took the limelight, there were sessions focused …
-
ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly
The past weekend has seen a number of major data presentations at the American Diabetes Association (ADA) conference 2026. While Clinical …
-
ADA26: key obesity readouts from the conference
As the 2026 American Diabetes Association (ADA) conference draws to a close for another year, Clinical Trials Arena gives you …
-
Pfizer reports positive results from Phase IIb trial of berobenatide
Pfizer has reported detailed Phase IIb results for its investigational monthly glucagon-like peptide-1 receptor agonist (GLP-1 RA) peptide, berobenatide (PF’3944), …
-
Novo Nordisk reports Phase II data for zenagamtide in diabetes
Novo Nordisk has reported results from its Phase II study of zenagamtide, an investigational once-weekly subcutaneous treatment, showing statistically significant …
-
Innovent eyes third-line nod for gastric cancer ADC on Phase III PFS hit
Takeda’s $11.4bn bet on assets from Chinese biotech, Innovent Biologics, is showing early signs of paying off, as the latter …
-
ASCO 2026: darovasertib raises the bar in metastatic uveal melanoma
At the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, held on 29 May - 2 June, primary results …
